22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
On December 16, 2019, the National Labor Relations Board (“NLRB”) issued a decision in Caesars Ent...
Read More >
M&A deal teams should take note of heightened scrutiny of HR and employment practices by antitrust e...
Read More >
On January 31, 2020, Health and Human Services Secretary Alex M. Azar II declared a public health em...
Read More >
Seyfarth Synopsis: The National Safety Council released a policy statement endorsing employer zero-t...
Read More >
The autumn leaves are turning, football season is gathering momentum, Congress is reconvening, and a...
Read More >
Good news for the motor carrier industry … for now. A federal judge has issued a temporary restrain...
Read More >